Your browser doesn't support javascript.
Prospective Observational COVID-19 Screening and Monitoring of Asymptomatic Cancer Center Health-Care Workers with a Rapid Serological Test.
Paradiso, Angelo Virgilio; De Summa, Simona; Silvestris, Nicola; Tommasi, Stefania; Tufaro, Antonio; Larocca, Angela Maria Vittoria; D'Addabbo, Vincenzo; Raffaele, Donata; Cafagna, Vito; Garrisi, Vito Michele; De Palma, Giuseppe.
  • Paradiso AV; Scientific Direction, IRCCS Istituto Tumori "Giovanni Paolo II", 70124 Bari, Italy.
  • De Summa S; Molecular Diagnostics and Pharmacogenetics Unit, IRCCS Istituto Tumori "Giovanni Paolo II", 70124 Bari, Italy.
  • Silvestris N; Unit of Internal Medicine "Guido Baccelli", Department of Biomedical Sciences and Human Oncology, University of Bari, 70124 Bari, Italy.
  • Tommasi S; Medical Oncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", 70124 Bari, Italy.
  • Tufaro A; Molecular Diagnostics and Pharmacogenetics Unit, IRCCS Istituto Tumori "Giovanni Paolo II", 70124 Bari, Italy.
  • Larocca AMV; Experimental Oncology and Biobank Management Unit, Institutional BioBank, IRCCS Istituto Tumori "Giovanni Paolo II", 70124 Bari, Italy.
  • D'Addabbo V; Hygiene Unit, University Hospital "Policlinico" of Bari, 70124 Bari, Italy.
  • Raffaele D; Professioni Sanitarie Unit, IRCCS Istituto Tumori "Giovanni Paolo II", 70124 Bari, Italy.
  • Cafagna V; Scientific Direction, IRCCS Istituto Tumori "Giovanni Paolo II", 70124 Bari, Italy.
  • Garrisi VM; Clinical Pathology Laboratory, IRCCS Istituto Tumori "Giovanni Paolo II", 70124 Bari, Italy.
  • De Palma G; Clinical Pathology Laboratory, IRCCS Istituto Tumori "Giovanni Paolo II", 70124 Bari, Italy.
Diagnostics (Basel) ; 11(6)2021 May 28.
Article in English | MEDLINE | ID: covidwho-1256436
ABSTRACT
Health-care workers (HCW) are at high risk for SARS-CoV-2 infection and, if asymptomatic, for transmitting the virus to fragile cancer patients. We monitored all asymptomatic HCWs of a cancer institute (94% of all employees agreed to enter the study) with the rapid serological test, VivaDiagTM, identifying SARS-CoV-2 associated-IgM/IgG. The tests were performed at time 0 (n = 606) and after 14 days (n = 393). Overall, the VivaDiagTM results of nine HCWs (1.5%) were positive, with one confirmed to be SARS-CoV-2-positive after oropharyngeal swab testing by RT-PCR. At time 0, all nine cases showed IgM expression while IgG was detected in only one. After 14 days, IgM persisted in all the cases, while IgG became evident in four. A chemiluminescence immunoassay (CLIA) confirmed IgM positivity in 5/13 VivaDiagTM positive cases and IgG positivity in 4/5 VivaDiagTM positive cases. Our study suggests that the VivaDiagTM test can be of help in identifying SARS-CoV-2 infected people in cohorts of subjects with a high prevalence.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study Language: English Year: 2021 Document Type: Article Affiliation country: Diagnostics11060975

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study Language: English Year: 2021 Document Type: Article Affiliation country: Diagnostics11060975